LENZ Therapeutics (Nasdaq:LENZ) - Stock Analysis
This Simply Wall St analysis of LENZ Therapeutics (Nasdaq:LENZ) highlights the company's valuation, growth prospects, and financial health. The stock is currently trading significantly below fair value estimates, with revenue projected to grow substantially, yet the company remains unprofitable. Recent news includes insider stock purchases, analyst EPS revisions, and updates on its presbyopia treatment, VIZZ.
President of LENZ Therapeutics Evert Schimmelpennink Buys 57% More Shares
LENZ Therapeutics President Evert Schimmelpennink recently increased his stake in the company by 57%, purchasing US$251k worth of shares at US$8.95 each. This significant insider buying activity, along with other insider purchases over the last year, indicates optimism about the company's future, despite its recent losses. Insiders now own about 2.5% of the company's shares.
Director at LENZ Therapeutics (LENZ) buys 5,592 shares in open-market trade
LENZ Therapeutics director George Jeffrey P. has reported an open-market purchase of 5,592 shares of common stock on March 27, 2026. The shares were acquired at a weighted average price of $8.9217, within a range of $8.80 to $9.12 per share, totaling approximately $50,000. Following this transaction, Mr. P. now directly holds 5,592 shares of LENZ common stock.
Lenz Therapeutics CFO Chevallard buys $64k in stock
Lenz Therapeutics' CFO, Daniel R. Chevallard, recently acquired 7,500 shares of the company's stock for $64,275. This insider purchase occurred while the stock (NASDAQ:LENZ) is trading near its 52-week low and is considered undervalued by InvestingPro analysis. The company also reported Q4 2025 earnings showing a strong cash position and initial revenue from its new presbyopia treatment, VIZZ.
Lenz Therapeutics director George buys $49,890 in stock By Investing.com
Lenz Therapeutics director George Jeffrey P. recently purchased 5,592 shares of the company's common stock for $49,890, at an average price of $8.92. This transaction occurred after the stock experienced a 24% decline over the past week. InvestingPro analysis suggests the stock is undervalued with a fair value of $13.80, indicating potential for upside.
LENZ Therapeutics (LENZ) CEO adds 28,089 shares in open-market stock purchase
LENZ Therapeutics CEO Evert B. Schimmelpennink recently bought 28,089 shares of the company's common stock in an open-market transaction. The purchase occurred on March 27, 2026, at a weighted average price of $8.9505 per share, ranging from $8.80 to $9.25. Following this acquisition, Schimmelpennink's direct ownership in LENZ Therapeutics now totals 77,289 shares.
Lenz Therapeutics Insider Bought Shares Worth $251,411, According to a Recent SEC Filing
An insider at Lenz Therapeutics, Inc. recently purchased shares valued at $251,411, as reported in a new SEC filing. The article, published on March 30, 2026, highlights this insider transaction for the biotechnology company, which is focused on developing eye drops for presbyopia. The company's stock, trading under LENZ on Nasdaq, has seen significant changes year-to-date and is actively developing product candidates LNZ100 and LNZ101.
Lenz Therapeutics director George buys $49,890 in stock
Lenz Therapeutics director George Jeffrey P. purchased 5,592 shares of common stock for $49,890, after the stock experienced a 24% plunge. This acquisition comes as the company is commercializing its new presbyopia treatment, VIZZ, and despite a recent quarterly net loss due to increased operating expenses. Analysts like H.C. Wainwright maintain a Buy rating, highlighting VIZZ's growth potential.
LENZ Therapeutics (LENZ) CFO buys 7,500 shares of stock
LENZ Therapeutics' Chief Financial Officer, Daniel R. Chevallard, recently purchased 7,500 shares of common stock at $8.57 per share in an open-market transaction. This acquisition increased his direct holdings in the company to 12,886 shares. The transaction, filed as a Form 4, indicates a positive insider sentiment for LENZ Therapeutics.
Analysts Just Slashed Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) EPS Numbers
Analysts have significantly revised down their forecasts for LENZ Therapeutics, Inc. (NASDAQ:LENZ) for 2026, cutting revenue estimates and increasing loss per share projections. The consensus revenue forecast is now US$28m, a substantial reduction from the previous US$50m, while losses are expected to increase to US$3.75 per share. This downgrade has also led to a 20% reduction in the consensus price target for the company.
Lenz Therapeutics Earnings Call: High Spend, Growing Traction
Lenz Therapeutics reported on its Q4 earnings, highlighting strong early adoption for its presbyopia drop despite significant launch-phase losses. The company is investing heavily in sales and marketing, expanding its sales force and launching a DTC campaign, supported by a healthy cash balance. While patient and prescriber traction is growing, the company faces challenges with high operating costs, low direct product gross margins, and the need to educate physicians to broaden treatment adoption.
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of "Moderate Buy" from Brokerages
LENZ Therapeutics (NASDAQ:LENZ) has received a "Moderate Buy" consensus rating from eight brokerages, with an average 12-month price target of $45.60. This comes despite the company missing Q4 earnings and revenue estimates, reporting EPS of ($1.16) versus an estimated ($0.91) and revenue of $1.59M against a $3.09M estimate. Institutional investors hold 54.32% of the stock, with several major firms recently increasing their positions, indicating strong interest despite mixed analyst revisions and a significant drop in stock price from its one-year high.
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Analysts have significantly cut their revenue estimates and increased loss per share forecasts for LENZ Therapeutics after its latest yearly report. The company missed revenue predictions and reported a larger-than-expected statutory loss. Despite the negative revisions and a 13% drop in the consensus price target, LENZ Therapeutics is still expected to experience revenue growth faster than the broader industry.
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Are Cutting Their Estimates: Here's What You Need To Know
LENZ Therapeutics (NASDAQ:LENZ) recently released its yearly report, revealing revenues of US$19m, missing analyst predictions, and a statutory loss of US$2.85 per share, exceeding forecasts. Analysts have since cut next year's revenue estimates to US$30.3m and increased loss per share forecasts to US$3.62, leading to a 13% drop in the consensus price target to US$44.43. Despite the downgraded outlook, the company is still expected to experience revenue growth significantly faster than the broader industry.
LENZ Therapeutics stock rating reiterated at Buy by H.C. Wainwright
H.C. Wainwright has reiterated a Buy rating for LENZ Therapeutics Inc (NASDAQ:LENZ) with a $56.00 price target, highlighting the company's aggressive commercial expansion of its VIZZ eye drop for presbyopia. Despite the stock trading near its 52-week low and a significant net loss in Q4 2025, analysts maintain a Strong Buy consensus, viewing the stock as undervalued based on its strong cash position and gross profit margin. The company is actively growing its sales force and targeting key prescribers to drive adoption of VIZZ.
LENZ Therapeutics Reports Fourth Quarter, Full-Year Financial Results as Sales of Presbyopia Drop Gain Momentum
LENZ Therapeutics reported its fourth quarter and full-year 2025 financial results, highlighting positive early sales momentum for its VIZZ (aceclidine ophthalmic solution) 1.44% eye drops for presbyopia. The company generated $1.6 million in product revenue in Q4 2025 from over 20,000 filled prescriptions, attributing this success to broad prescriber uptake and encouraging refill dynamics. LENZ also announced expansion of its sales force, new commercialization partnerships, and international regulatory filings, while noting a net loss of $35.9 million for Q4 2025 and $82.1 million for the full year.
LENZ Therapeutics (NASDAQ:LENZ) Posts Earnings Results, Misses Expectations By $0.25 EPS
LENZ Therapeutics (NASDAQ:LENZ) reported its earnings results, missing consensus estimates by $0.25 EPS with a reported ($1.16) earnings per share and revenue of $1.59 million against an expected $3.09 million. The company highlighted early commercial traction for its LNZ100 (VIZZ) product, with over 45,000 monthly packs sold and an expanding sales force, while noting a significant quarterly cash burn of approximately $32 million. Despite a strong cash position of $292.3 million and no debt, the focus remains on scaling sales and marketing efforts and pursuing ex-U.S. approvals for 2027.
LENZ: Initial VIZZ launch drove $1.6M sales and $17.5M license revenue, but net loss reached $82.1M
LENZ VIZZ, an FDA-approved eye drop for presbyopia, generated $1.6 million in initial sales and $17.5 million in license revenue following its late 2025 launch. Despite these revenues, LENZ posted a net loss of $82.1 million, primarily due to significant commercial investments. The company maintains strong cash reserves to support its ongoing U.S. and international expansion efforts.
VIZZ presbyopia launch propels LENZ Therapeutics (NASDAQ: LENZ)
LENZ Therapeutics has officially launched VIZZ (aceclidine ophthalmic solution) 1.44% in the U.S. for presbyopia, aiming for a significant share of the estimated $3 billion market. The FDA-approved, once-daily eye drop demonstrated rapid and durable near-vision improvement in Phase 3 CLARITY trials without negatively impacting distance vision. LENZ is employing a dual commercialization strategy, targeting eye care professionals and launching a direct-to-consumer campaign, while also pursuing international partnerships and regulatory approvals to expand VIZZ's global reach.
LENZ Therapeutics, Inc. (LENZ) reports Q4 loss, misses revenue estimates
LENZ Therapeutics, Inc. reported a significant loss in its fourth quarter, missing revenue estimates. The company posted a net loss of $28.3 million, or $1.00 per share, which was wider than the prior year's loss. Analysts had expected a smaller loss per share and higher revenues, highlighting a challenging quarter for the biopharmaceutical firm.
LENZ Therapeutics, Inc. (LENZ) Reports Wider Q4 Loss Than Expected
LENZ Therapeutics, Inc. (LENZ) reported a wider-than-expected loss of $1.16 per share in Q4 2025, missing analyst estimates of a $0.99 loss, due to the cash-intensive commercial launch of its presbyopia treatment. The company generated $1.6 million in revenue and posted a net loss of $35.9 million, but showed traction with 20,000 paid prescriptions filled and its prescriber base expanding to 6,500 unique prescribers.
LENZ Therapeutics, Inc. (LENZ) Reports Q4 Loss, Misses Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) reported a Q4 loss of $1.16 per share, missing the Zacks Consensus Estimate of a $0.91 loss, and also fell short on revenue expectations with $1.59 million against an estimate of $4.78 million. The company's stock has underperformed the S&P 500 this year, declining 31.3% compared to the S&P's 3.9% drop. LENZ currently holds a Zacks Rank #3 (Hold).
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
LENZ Therapeutics reported its Q4 and full-year 2025 financial results, highlighting the successful commercial launch of VIZZ® (aceclidine ophthalmic solution) 1.44% for presbyopia. The company generated $1.6 million in net product revenue during its first quarter of launch and is on pace for over 45,000 filled prescriptions by Q1 2026. LENZ also announced expansion of its sales organization and global regulatory efforts, including a Marketing Authorization Application submission to the EMA.
LENZ Therapeutics, Inc. (LENZ) Announces Fourth Quarter Loss, Falls Short of Revenue Projections
LENZ Therapeutics, Inc. (LENZ) reported a wider-than-expected loss of $1.16 per share for the fourth quarter, missing Zacks Consensus Estimates and revenue projections. The company posted $1.59 million in revenue, significantly below consensus, and its shares have declined by over 31% year-to-date. Despite the underperformance, investor attention is now on future earnings outlooks and analyst revisions.
LENZ Therapeutics Hits 52-Week Low at USD 10.44 Amid Ongoing Struggles
LENZ Therapeutics, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 10.44 as of March 20, 2026. The company is facing significant financial struggles, evidenced by negative operating and net profits, a precarious debt-to-equity ratio of -1.04, and a largely negative return on equity. With a market capitalization of USD 367 million, LENZ Therapeutics' stock performance reflects broader industry challenges and a lack of dividend yield.
LENZ Therapeutics Hits 52-Week Low at USD 11.22 Amidst Declining Performance
LENZ Therapeutics, Inc. has reached a new 52-week low of USD 11.22, reflecting significant financial struggles within the Pharmaceuticals & Biotechnology sector. The company reported substantial quarterly losses, a negative return on equity, and no dividend yield, contrasting sharply with the S&P 500's performance. These figures underscore the challenging market environment and financial headwinds LENZ Therapeutics is currently facing.
Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings
LENZ Therapeutics (NASDAQ: LENZ) is set to release its Q4 earnings on Tuesday, March 24, with analysts expecting a larger quarterly loss of 90 cents per share compared to 46 cents last year, despite anticipated revenue of $3.09 million. The company recently submitted a marketing authorization application to the EMA for VIZZ to treat presbyopia, and its stock saw a 5% gain on Monday. Several top Wall Street analysts have recently reiterated Buy/Outperform ratings and increased price targets for LENZ Therapeutics.
LENZ Therapeutics (NASDAQ:LENZ) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen has downgraded LENZ Therapeutics (NASDAQ:LENZ) from a "hold" to a "sell" rating. Despite this, the stock maintains a "Moderate Buy" consensus rating among analysts with an average price target of $55.50. Shares of LENZ Therapeutics fell by 8.8% to $10.48, and institutional investors hold a significant 54.32% stake in the company.
LENZ Therapeutics Inc expected to post a loss of 97 cents a share - Earnings Preview
LENZ Therapeutics Inc is projected to report a loss of 97 cents per share. This information comes from an earnings preview. The article is a short news piece from Reuters.
Maker of VIZZ presbyopia eye drop sets March 24 call on 2025 results
LENZ Therapeutics (Nasdaq: LENZ) has announced it will report its Q4 and full year 2025 financial results and recent corporate highlights on Tuesday, March 24, 2026. The event will include a live webcast and telephone conference starting at 8:30 a.m. EDT. The company, known for its FDA-approved VIZZ eye drop for presbyopia, has seen positive market reaction to similar news in the past.
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026
LENZ Therapeutics, Inc. announced it will host a webcast on March 24, 2026, to discuss its fourth quarter and full year 2025 financial results and recent corporate highlights. The pharmaceutical company specializes in VIZZ® (aceclidine ophthalmologic solution) 1.44%, an FDA-approved eye drop for presbyopia. A live webcast and subsequent replay will be available on the company's website.
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026
LENZ Therapeutics announced it will report its fourth quarter and full year 2025 financial results and recent corporate highlights on Tuesday, March 24, 2026, via a webcast and conference call. The company specializes in the commercialization of VIZZ®, an FDA-approved eye drop for presbyopia. A replay of the webcast will be available on their website after the event.
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026
LENZ Therapeutics announced it will host a webcast on March 24, 2026, at 8:30 a.m. EDT to report its fourth quarter and full year 2025 financial results and recent corporate highlights. The company, focused on commercializing VIZZ® (aceclidine ophthalmologic solution) 1.44% for presbyopia, will provide webcast access for investors and make a replay available on its website.
693,044 Shares in LENZ Therapeutics, Inc. $LENZ Acquired by First Light Asset Management LLC
First Light Asset Management LLC recently acquired 693,044 shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ), valued at approximately $32.28 million, making it their 10th largest holding and representing 2.21% of the company. Several other institutional investors also adjusted their positions in LENZ Therapeutics during recent quarters. Wall Street analysts currently have a consensus "Moderate Buy" rating for LENZ, with a target price of $56.40, as the biopharmaceutical company continues Phase III clinical trials for its presbyopia therapies.
LENZ Therapeutics, Inc. $LENZ is Ally Bridge Group NY LLC's 7th Largest Position
Ally Bridge Group NY LLC significantly reduced its stake in LENZ Therapeutics ($LENZ) by 48.9% in Q3, making it their 7th largest position. Despite this sale, other institutional investors like Versant Venture Management, Adage Capital Partners, and Franklin Resources increased their holdings, bringing total institutional ownership to 54.32%. Analysts have a "Moderate Buy" consensus rating with a price target of $56.40, while LENZ trades around $12.15.
LENZ Therapeutics (LENZ) Projected to Post Earnings on Wednesday
LENZ Therapeutics (NASDAQ:LENZ) is projected to release its Q4 2025 earnings before the market opens on Wednesday, March 18, 2026. Analysts expect the company to report earnings of ($0.91) per share and revenue of $3.088 million. Institutional investors have recently increased their stakes in LENZ, which currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $56.40.
LENZ submits marketing application for presbyopia drug in Europe
LENZ Therapeutics, Inc. has submitted a Marketing Authorization Application to the European Medicines Agency for VIZZ (aceclidine ophthalmic solution) 1.44%, an eye drop for treating presbyopia. This marks the fifth regulatory filing outside the U.S., supported by Phase 3 trial data showing improved near vision for up to 10 hours without serious adverse events. Despite a significant stock drop, Wall Street analysts maintain a "Strong Buy" rating, anticipating commercialization in Europe through strategic partnerships, while also noting recent revenue exceeding estimates and a reported case of retinal tear.
William Blair Maintains Outperform on LENZ Therapeutics, Inc (LENZ) March 10 2026
William Blair has reiterated an "Outperform" rating on LENZ Therapeutics, Inc. (LENZ) on March 10, 2026, driven by continued belief in the blockbuster potential of its product, VIZZ. This maintenance of rating signals William Blair's favorable risk-reward outlook for LENZ, though it did not include a new price target. Despite a slight intraday pullback of -2.71% following the announcement, Meyka AI rates LENZ with a B+ grade, considering various financial and market factors.
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia
LENZ Therapeutics has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for VIZZ® (aceclidine ophthalmic solution) 1.44% to treat presbyopia in adults. This submission is supported by positive data from three Phase 3 CLARITY trials, which showed VIZZ improved near vision within 30 minutes for up to 10 hours and was well-tolerated. VIZZ is already approved and commercially available in the U.S., and this MAA represents a significant step in LENZ's global expansion strategy.
LENZ: Rapidly growing prescriber base and strong refill rates highlight successful launch momentum
A novel presbyopia eye drop from LENZ Therapeutics (LENZ) is experiencing a successful launch, marked by rapid and sustained efficacy, strong safety, and high adoption and refill rates. Early DTC campaigns and an expanding prescriber base are increasing awareness, with international expansion also underway. This success is evidenced by insights from the Leerink Global Healthcare Conference 2026.
LENZ submits marketing application for presbyopia drug in Europe By Investing.com
LENZ Therapeutics, Inc. has submitted a Marketing Authorization Application to the European Medicines Agency for VIZZ, an eye drop to treat presbyopia. This marks the fifth regulatory filing outside the U.S. for VIZZ, which received FDA approval in July 2025 and is commercially available in the U.S. Despite a significant stock drop, analysts maintain a "Strong Buy" consensus, and the company plans strategic partnerships for commercialization in Europe.
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ for the Treatment of Presbyopia
LENZ Therapeutics has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for VIZZ (aceclidine ophthalmic solution) 1.44%, an eye drop for presbyopia treatment. This marks the fifth ex-U.S. regulatory submission for VIZZ, which was approved by the U.S. FDA in July 2025 and is commercially available there. The submission is supported by positive Phase 3 clinical data, and LENZ plans to pursue commercialization in Europe through strategic partnerships, aiming to address the significant market of 1.8 billion people globally affected by presbyopia.
New eye drop for age-related blurry vision heads to EU review
LENZ Therapeutics (NASDAQ: LENZ) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for VIZZ® (aceclidine ophthalmic solution) 1.44% to treat presbyopia. This marks the fifth ex-U.S. regulatory submission for VIZZ, following its U.S. FDA approval in July 2025. The submission is supported by positive data from three Phase 3 CLARITY trials, which demonstrated improved near vision within 30 minutes for up to 10 hours with a favorable safety profile.
Tyro Capital Management LLC Makes New $4.69 Million Investment in LENZ Therapeutics, Inc. $LENZ
Tyro Capital Management LLC has made a new investment of $4.69 million in LENZ Therapeutics, Inc. (NASDAQ:LENZ), acquiring 100,672 shares in the third quarter. This investment represents 1.7% of Tyro Capital Management's total holdings, making LENZ Therapeutics its 10th largest position. Other institutional investors also increased their stakes, leading to a total institutional ownership of 54.32% in the company, which analysts have given a consensus "Moderate Buy" rating with a target price significantly above its current trading price.
Presbyopia Pipeline 2026: 10+ Companies, 10+ Emerging Therapies, and 3 Key FDA NDA Milestones Driving the Future of Vision Care, analyses DelveInsight
DelveInsight's "Presbyopia Pipeline Insight 2026" report analyzes over 10 companies and 10 investigational therapies addressing presbyopia, a common age-related vision condition. Key highlights include recent FDA approvals for Yuvezzi and VIZZ, as well as upcoming PDUFA dates and NDA submissions from companies like Viatris, LENZ Therapeutics, and Tenpoint Therapeutics. The report details the mechanisms of action for promising therapies such as LNZ100 by Lenz Therapeutics and GLK-302 by Glaukos Corporation, emphasizing the growing interest and innovation in this therapeutic area.
LENZ: Strong launch momentum for a new presbyopia eye drop, with robust efficacy and market uptake
A new presbyopia eye drop from LENZ, launched in October, is demonstrating strong efficacy and safety, leading to rapid adoption by doctors and patients. Direct-to-consumer campaigns and sales force expansion are increasing awareness for the product, which targets a large and underdeveloped market. Early refill rates are encouraging, indicating significant growth potential.
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of "Moderate Buy" by Brokerages
LENZ Therapeutics (NASDAQ: LENZ) has received an average rating of "Moderate Buy" from brokerages, based on reports from seven analysts. The company currently develops LNZ100 and LNZ101 for presbyopia, which are in Phase III clinical trials. Despite some downgrades to "hold" by Zacks Research and Wall Street Zen, five analysts maintain a "buy" rating, with an average one-year price target of $56.40.
LENZ Therapeutics (NASDAQ:LENZ) Upgraded by Wall Street Zen to Hold Rating
Wall Street Zen has upgraded LENZ Therapeutics (NASDAQ:LENZ) from a "sell" to a "hold" rating. The stock has a "Moderate Buy" average rating from analysts with an average target price of $56.40, significantly higher than its current trading price of around $13.49. Institutional investors and hedge funds have shown considerable interest, with several increasing their stakes in the biopharmaceutical company which is currently conducting Phase III trials for its presbyopia treatments.
Versant Venture Management LLC Buys Shares of 2,656,888 LENZ Therapeutics, Inc. $LENZ
Versant Venture Management LLC has acquired a new position of 2,656,888 shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) valued at approximately $123.76 million, making it 58.3% of Versant’s investment portfolio. Other institutional investors like Adage Capital Partners, Saturn V Capital Management, Invesco Ltd., Stempoint Capital LP, and Candriam S.C.A. also increased or started new positions, resulting in 54.32% institutional ownership. LENZ Therapeutics, with a market cap of $372.04 million, currently holds a "Moderate Buy" analyst consensus with an average target price of $56.40, despite recent downgrades.
Presbyopia eye-drop firm LENZ lines up two investor conferences
LENZ Therapeutics announced it will present at two investor conferences in early March 2026: the TD Cowen 46th Annual Health Care Conference and the Leerink Partners 2026 Global Healthcare Conference. Management will participate in fireside chats with live audio webcasts and one-on-one investor meetings at both events. The company, focused on commercializing VIZZ® (aceclidine ophthalmic solution) 1.44% for presbyopia, saw a moderate positive market reaction of +2.59% on the day this news was published.
